ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Pulmonary Hypertension Drug Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-33T9683
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Pulmonary Hypertension Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Pulmonary Hypertension Drug Market Research Report 2025

Code: QYRE-Auto-33T9683
Report
January 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
Vectura Group plc
Bayer
Ikaria Inc.
Proreo Pharma AG
Vicore Pharma AB
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals Co Ltd

Pulmonary Hypertension Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Pulmonary Hypertension Drug Market

Pulmonary Hypertension Drug Market

The global market for Pulmonary Hypertension Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Pulmonary Hypertension Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Hypertension Drug.
The Pulmonary Hypertension Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pulmonary Hypertension Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Hypertension Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Pulmonary Hypertension Drug Market Report

Report Metric Details
Report Name Pulmonary Hypertension Drug Market
CAGR 5%
Segment by Type
Segment by Application
  • Clinic
  • Hospital
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi, Vectura Group plc, Bayer AG, Ikaria Inc., Proreo Pharma AG, Vicore Pharma AB, Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Pulmonary Hypertension Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Pulmonary Hypertension Drug Market report?

Ans: The main players in the Pulmonary Hypertension Drug Market are Sanofi, Vectura Group plc, Bayer AG, Ikaria Inc., Proreo Pharma AG, Vicore Pharma AB, Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd.

What are the Application segmentation covered in the Pulmonary Hypertension Drug Market report?

Ans: The Applications covered in the Pulmonary Hypertension Drug Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the Pulmonary Hypertension Drug Market report?

Ans: The Types covered in the Pulmonary Hypertension Drug Market report are IK-3001, Sildenafil Citrate IMD, IK-7002, Riociguat, SAR-407899, Others

Recommended Reports

Cardiovascular Drugs

Respiratory Therapeutics

Pharmaceutical Treatments

1 Pulmonary Hypertension Drug Market Overview
1.1 Product Definition
1.2 Pulmonary Hypertension Drug by Type
1.2.1 Global Pulmonary Hypertension Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 IK-3001
1.2.3 Sildenafil Citrate IMD
1.2.4 IK-7002
1.2.5 Riociguat
1.2.6 SAR-407899
1.2.7 Others
1.3 Pulmonary Hypertension Drug by Application
1.3.1 Global Pulmonary Hypertension Drug Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Pulmonary Hypertension Drug Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Hypertension Drug Revenue 2020-2031
1.4.2 Global Pulmonary Hypertension Drug Sales 2020-2031
1.4.3 Global Pulmonary Hypertension Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Pulmonary Hypertension Drug Market Competition by Manufacturers
2.1 Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Pulmonary Hypertension Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Pulmonary Hypertension Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pulmonary Hypertension Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Hypertension Drug, Product Type & Application
2.7 Global Key Manufacturers of Pulmonary Hypertension Drug, Date of Enter into This Industry
2.8 Global Pulmonary Hypertension Drug Market Competitive Situation and Trends
2.8.1 Global Pulmonary Hypertension Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Pulmonary Hypertension Drug Players Market Share by Revenue
2.8.3 Global Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Pulmonary Hypertension Drug Market Scenario by Region
3.1 Global Pulmonary Hypertension Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Pulmonary Hypertension Drug Sales by Region: 2020-2031
3.2.1 Global Pulmonary Hypertension Drug Sales by Region: 2020-2025
3.2.2 Global Pulmonary Hypertension Drug Sales by Region: 2026-2031
3.3 Global Pulmonary Hypertension Drug Revenue by Region: 2020-2031
3.3.1 Global Pulmonary Hypertension Drug Revenue by Region: 2020-2025
3.3.2 Global Pulmonary Hypertension Drug Revenue by Region: 2026-2031
3.4 North America Pulmonary Hypertension Drug Market Facts & Figures by Country
3.4.1 North America Pulmonary Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Pulmonary Hypertension Drug Sales by Country (2020-2031)
3.4.3 North America Pulmonary Hypertension Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pulmonary Hypertension Drug Market Facts & Figures by Country
3.5.1 Europe Pulmonary Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Pulmonary Hypertension Drug Sales by Country (2020-2031)
3.5.3 Europe Pulmonary Hypertension Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Hypertension Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Pulmonary Hypertension Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Pulmonary Hypertension Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pulmonary Hypertension Drug Market Facts & Figures by Country
3.7.1 Latin America Pulmonary Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Pulmonary Hypertension Drug Sales by Country (2020-2031)
3.7.3 Latin America Pulmonary Hypertension Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Hypertension Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Hypertension Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pulmonary Hypertension Drug Sales by Type (2020-2031)
4.1.1 Global Pulmonary Hypertension Drug Sales by Type (2020-2025)
4.1.2 Global Pulmonary Hypertension Drug Sales by Type (2026-2031)
4.1.3 Global Pulmonary Hypertension Drug Sales Market Share by Type (2020-2031)
4.2 Global Pulmonary Hypertension Drug Revenue by Type (2020-2031)
4.2.1 Global Pulmonary Hypertension Drug Revenue by Type (2020-2025)
4.2.2 Global Pulmonary Hypertension Drug Revenue by Type (2026-2031)
4.2.3 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2020-2031)
4.3 Global Pulmonary Hypertension Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Pulmonary Hypertension Drug Sales by Application (2020-2031)
5.1.1 Global Pulmonary Hypertension Drug Sales by Application (2020-2025)
5.1.2 Global Pulmonary Hypertension Drug Sales by Application (2026-2031)
5.1.3 Global Pulmonary Hypertension Drug Sales Market Share by Application (2020-2031)
5.2 Global Pulmonary Hypertension Drug Revenue by Application (2020-2031)
5.2.1 Global Pulmonary Hypertension Drug Revenue by Application (2020-2025)
5.2.2 Global Pulmonary Hypertension Drug Revenue by Application (2026-2031)
5.2.3 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2020-2031)
5.3 Global Pulmonary Hypertension Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Pulmonary Hypertension Drug Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Vectura Group plc
6.2.1 Vectura Group plc Company Information
6.2.2 Vectura Group plc Description and Business Overview
6.2.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
6.2.5 Vectura Group plc Recent Developments/Updates
6.3 Bayer AG
6.3.1 Bayer AG Company Information
6.3.2 Bayer AG Description and Business Overview
6.3.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bayer AG Pulmonary Hypertension Drug Product Portfolio
6.3.5 Bayer AG Recent Developments/Updates
6.4 Ikaria Inc.
6.4.1 Ikaria Inc. Company Information
6.4.2 Ikaria Inc. Description and Business Overview
6.4.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio
6.4.5 Ikaria Inc. Recent Developments/Updates
6.5 Proreo Pharma AG
6.5.1 Proreo Pharma AG Company Information
6.5.2 Proreo Pharma AG Description and Business Overview
6.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
6.5.5 Proreo Pharma AG Recent Developments/Updates
6.6 Vicore Pharma AB
6.6.1 Vicore Pharma AB Company Information
6.6.2 Vicore Pharma AB Description and Business Overview
6.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
6.6.5 Vicore Pharma AB Recent Developments/Updates
6.7 Biolab Sanus Farmaceutica Ltda.
6.7.1 Biolab Sanus Farmaceutica Ltda. Company Information
6.7.2 Biolab Sanus Farmaceutica Ltda. Description and Business Overview
6.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
6.7.5 Biolab Sanus Farmaceutica Ltda. Recent Developments/Updates
6.8 Hanmi Pharmaceuticals, Co. Ltd.
6.8.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
6.8.2 Hanmi Pharmaceuticals, Co. Ltd. Description and Business Overview
6.8.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
6.8.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pulmonary Hypertension Drug Industry Chain Analysis
7.2 Pulmonary Hypertension Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Hypertension Drug Production Mode & Process Analysis
7.4 Pulmonary Hypertension Drug Sales and Marketing
7.4.1 Pulmonary Hypertension Drug Sales Channels
7.4.2 Pulmonary Hypertension Drug Distributors
7.5 Pulmonary Hypertension Drug Customer Analysis
8 Pulmonary Hypertension Drug Market Dynamics
8.1 Pulmonary Hypertension Drug Industry Trends
8.2 Pulmonary Hypertension Drug Market Drivers
8.3 Pulmonary Hypertension Drug Market Challenges
8.4 Pulmonary Hypertension Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Sanofi
Vectura Group plc
Bayer
Ikaria Inc.
Proreo Pharma AG
Vicore Pharma AB
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals Co Ltd
List of Tables
 Table 1. Global Pulmonary Hypertension Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Pulmonary Hypertension Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Pulmonary Hypertension Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Pulmonary Hypertension Drug Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Pulmonary Hypertension Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Pulmonary Hypertension Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Pulmonary Hypertension Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Pulmonary Hypertension Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Pulmonary Hypertension Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Pulmonary Hypertension Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Pulmonary Hypertension Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Pulmonary Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Hypertension Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Pulmonary Hypertension Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Pulmonary Hypertension Drug Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Pulmonary Hypertension Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Pulmonary Hypertension Drug Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Pulmonary Hypertension Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Pulmonary Hypertension Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Pulmonary Hypertension Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Pulmonary Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Pulmonary Hypertension Drug Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Pulmonary Hypertension Drug Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Pulmonary Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Pulmonary Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Pulmonary Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Pulmonary Hypertension Drug Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Pulmonary Hypertension Drug Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Pulmonary Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Pulmonary Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Pulmonary Hypertension Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Pulmonary Hypertension Drug Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Pulmonary Hypertension Drug Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Pulmonary Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Pulmonary Hypertension Drug Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Pulmonary Hypertension Drug Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Pulmonary Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Pulmonary Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Pulmonary Hypertension Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Pulmonary Hypertension Drug Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Pulmonary Hypertension Drug Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Pulmonary Hypertension Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Pulmonary Hypertension Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Pulmonary Hypertension Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Pulmonary Hypertension Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Pulmonary Hypertension Drug Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Pulmonary Hypertension Drug Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Pulmonary Hypertension Drug Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Pulmonary Hypertension Drug Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Pulmonary Hypertension Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Pulmonary Hypertension Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Pulmonary Hypertension Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Pulmonary Hypertension Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Pulmonary Hypertension Drug Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Pulmonary Hypertension Drug Price (USD/Pcs) by Application (2026-2031)
 Table 70. Sanofi Company Information
 Table 71. Sanofi Description and Business Overview
 Table 72. Sanofi Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Sanofi Pulmonary Hypertension Drug Product
 Table 74. Sanofi Recent Developments/Updates
 Table 75. Vectura Group plc Company Information
 Table 76. Vectura Group plc Description and Business Overview
 Table 77. Vectura Group plc Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Vectura Group plc Pulmonary Hypertension Drug Product
 Table 79. Vectura Group plc Recent Developments/Updates
 Table 80. Bayer AG Company Information
 Table 81. Bayer AG Description and Business Overview
 Table 82. Bayer AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Bayer AG Pulmonary Hypertension Drug Product
 Table 84. Bayer AG Recent Developments/Updates
 Table 85. Ikaria Inc. Company Information
 Table 86. Ikaria Inc. Description and Business Overview
 Table 87. Ikaria Inc. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Ikaria Inc. Pulmonary Hypertension Drug Product
 Table 89. Ikaria Inc. Recent Developments/Updates
 Table 90. Proreo Pharma AG Company Information
 Table 91. Proreo Pharma AG Description and Business Overview
 Table 92. Proreo Pharma AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Proreo Pharma AG Pulmonary Hypertension Drug Product
 Table 94. Proreo Pharma AG Recent Developments/Updates
 Table 95. Vicore Pharma AB Company Information
 Table 96. Vicore Pharma AB Description and Business Overview
 Table 97. Vicore Pharma AB Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. Vicore Pharma AB Pulmonary Hypertension Drug Product
 Table 99. Vicore Pharma AB Recent Developments/Updates
 Table 100. Biolab Sanus Farmaceutica Ltda. Company Information
 Table 101. Biolab Sanus Farmaceutica Ltda. Description and Business Overview
 Table 102. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product
 Table 104. Biolab Sanus Farmaceutica Ltda. Recent Developments/Updates
 Table 105. Hanmi Pharmaceuticals, Co. Ltd. Company Information
 Table 106. Hanmi Pharmaceuticals, Co. Ltd. Description and Business Overview
 Table 107. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product
 Table 109. Hanmi Pharmaceuticals, Co. Ltd. Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Pulmonary Hypertension Drug Distributors List
 Table 113. Pulmonary Hypertension Drug Customers List
 Table 114. Pulmonary Hypertension Drug Market Trends
 Table 115. Pulmonary Hypertension Drug Market Drivers
 Table 116. Pulmonary Hypertension Drug Market Challenges
 Table 117. Pulmonary Hypertension Drug Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Pulmonary Hypertension Drug
 Figure 2. Global Pulmonary Hypertension Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Pulmonary Hypertension Drug Market Share by Type: 2024 & 2031
 Figure 4. IK-3001 Product Picture
 Figure 5. Sildenafil Citrate IMD Product Picture
 Figure 6. IK-7002 Product Picture
 Figure 7. Riociguat Product Picture
 Figure 8. SAR-407899 Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global Pulmonary Hypertension Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Pulmonary Hypertension Drug Market Share by Application: 2024 & 2031
 Figure 12. Clinic
 Figure 13. Hospital
 Figure 14. Others
 Figure 15. Global Pulmonary Hypertension Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Pulmonary Hypertension Drug Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Pulmonary Hypertension Drug Sales (2020-2031) & (K Pcs)
 Figure 18. Global Pulmonary Hypertension Drug Average Price (USD/Pcs) & (2020-2031)
 Figure 19. Pulmonary Hypertension Drug Report Years Considered
 Figure 20. Pulmonary Hypertension Drug Sales Share by Manufacturers in 2024
 Figure 21. Global Pulmonary Hypertension Drug Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Pulmonary Hypertension Drug Players: Market Share by Revenue in Pulmonary Hypertension Drug in 2024
 Figure 23. Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Pulmonary Hypertension Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Pulmonary Hypertension Drug Sales Market Share by Country (2020-2031)
 Figure 26. North America Pulmonary Hypertension Drug Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Pulmonary Hypertension Drug Sales Market Share by Country (2020-2031)
 Figure 30. Europe Pulmonary Hypertension Drug Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Pulmonary Hypertension Drug Revenue Market Share by Region (2020-2031)
 Figure 38. China Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Pulmonary Hypertension Drug Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Pulmonary Hypertension Drug Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Pulmonary Hypertension Drug Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. U.A.E Pulmonary Hypertension Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Pulmonary Hypertension Drug by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Pulmonary Hypertension Drug by Type (2020-2031)
 Figure 60. Global Pulmonary Hypertension Drug Price (USD/Pcs) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Pulmonary Hypertension Drug by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Pulmonary Hypertension Drug by Application (2020-2031)
 Figure 63. Global Pulmonary Hypertension Drug Price (USD/Pcs) by Application (2020-2031)
 Figure 64. Pulmonary Hypertension Drug Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Pulmonary Arterial Hypertension PAH Drugs Market Research Report 2025
Pulmonary Arterial Hypertension PAH Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hypertensive Heart Disease Drug Market Research Report 2025
Global Pulmonary Embolism Drug Market Research Report 2025
Anti Hypertensive Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pulmonary Drug Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hypertension and Heart Failure Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Proton Pump Inhibitor Drug Market Research Report 2025
Global Antihypertensive Agents Market Research Report 2024
Global Sildenafil Drug Market Research Report 2025
Cardiovascular Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Idiopathic Pulmonary Fibrosis Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cardiovascular Disease Nursing Drugs Market Research Report 2025
Cardiovascular Therapeutic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cardiogenic Shock Drug Market Research Report 2025
Cardiovascular Drug Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cardiac Drug Balloon Market Research Report 2025
Medication for Portal Hypertension Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Emphysema Drug Market Research Report 2025
Cardiac Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Cardiovascular Informations (CVIS) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10A6248
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8I7059
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Heparin Calcium Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15Y8668
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions